New drug combo targets Hard-to-Treat kidney cancer
NCT ID NCT05536141
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- casdatifan (AB521), cabozantinib, zimberelimab, ipilimumab
- What this could lead to
- If successful, this could point toward a new treatment option for advanced kidney cancer and other solid tumors.
- What could go wrong
- This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBirmingham, Alabama, 35294, United States
-
Research Site
RECRUITINGSan Diego, California, 92093, United States
-
Research Site
RECRUITINGSanta Monica, California, 90404, United States
-
Research Site
RECRUITINGMiami, Florida, 33136, United States
-
Research Site
RECRUITINGAtlanta, Georgia, 30322-1013, United States
-
Research Site
RECRUITINGLouisville, Kentucky, 40202, United States
-
Research Site
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Research Site
RECRUITINGBaltimore, Maryland, 21287, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGDetroit, Michigan, 48201, United States
-
Research Site
RECRUITINGDetroit, Michigan, 48202, United States
-
Research Site
RECRUITINGOmaha, Nebraska, 68124, United States
-
Research Site
RECRUITINGNew York, New York, 10029, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Research Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37240, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
NOT_YET_RECRUITINGCamperdown, Australia
-
Research Site
RECRUITINGMelbourne, Australia
-
Research Site
RECRUITINGSydney, Australia
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGBarcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.